PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 10928971-0 2000 FK506 potently inhibits T cell activation induced TNF-alpha and IL-1beta production in vitro by human peripheral blood mononuclear cells. Tacrolimus 0-5 tumor necrosis factor Homo sapiens 50-59 10928971-1 2000 The aim of this study was to elucidate the in vitro inhibitory potency of FK506 on production of the inflammatory cytokines, tumour necrosis factor (TNF)-alpha and interleukin (IL)-1beta, with a view to assessing this immunosuppressive agent as a potential anti-rheumatic drug. Tacrolimus 74-79 tumor necrosis factor Homo sapiens 125-159 10928971-4 2000 FK506 inhibited anti-CD3/CD28 induced TNF-alpha and IL-1beta production at concentrations less than 1 ng ml(-1). Tacrolimus 0-5 tumor necrosis factor Homo sapiens 38-47 10928971-5 2000 Flow cytometric analysis of intracellular TNF-alpha and IL-1beta positive cells showed that FK506 potently suppresses inflammatory cytokine production from CD14+ monocytes as well as from T cells. Tacrolimus 92-97 tumor necrosis factor Homo sapiens 42-51 9878113-0 1998 Distinctive calcineurin-dependent (FK506-sensitive) mechanisms regulate the production of the CC chemokines macrophage inflammatory protein (MIP)-1alpha, MIP-1beta, and RANTES vs IL-2 and TNF-alpha by activated human T cells. Tacrolimus 35-40 tumor necrosis factor Homo sapiens 188-197 34607938-9 2021 In vitro treatment of healthy CD4+ and CD8+ T cells with tacrolimus abrogated the proliferation and cytokine (INF-gamma, IL-2, and TNF-alpha) secretion associated with the type 1 inflammatory phenotype observed in pre- and post-PTx rejectors. Tacrolimus 57-67 tumor necrosis factor Homo sapiens 131-140 8816436-2 1996 In both cases, induction of TNF-alpha gene transcription can be blocked by the immunosuppressants cyclosporin A and FK506, which suggested a role for the NFAT family of proteins in the regulation of the gene in B cells. Tacrolimus 116-121 tumor necrosis factor Homo sapiens 28-37 7507316-6 1993 For instance, CsA and FK 506 inhibit the transcription of IL-3, IL-4, IFN gamma, TNF alpha or GM-CSF by activated T cells, and rapamycin has been shown to block the response to various growth factors such as IL-3, IL-4 or IL-6. Tacrolimus 22-28 tumor necrosis factor Homo sapiens 81-90 8377379-0 1993 CsA, FK506, corticosteroids and rapamycin inhibit TNF alpha production by cultured PTEC. Tacrolimus 5-10 tumor necrosis factor Homo sapiens 50-59 8377379-6 1993 FK506, corticosteroids and rapamycin also inhibited TNF alpha production in a dose dependent fashion, although not as effectively as CsA. Tacrolimus 0-5 tumor necrosis factor Homo sapiens 52-61 1371491-8 1992 When the cells were stimulated by phorbol ester (phorbol 12-myristate 13-acetate, PMA) plus calcium ionophore (ionomycin), FK506 and CsA inhibited, in a dose-dependent manner, the production of IL-2, IL-4, IL-5, IFN-gamma and TNF-alpha. Tacrolimus 123-128 tumor necrosis factor Homo sapiens 226-235 1371491-12 1992 Depending on the mode of cell activation the two drugs inhibited not only cytokine production in lymphocytes but also antigen-induced monokine (TNF-alpha) production in macrophages, although the optimal immunomodulatory effect of FK506 was achieved at a concentration approximately 50-fold lower than that of CsA. Tacrolimus 230-235 tumor necrosis factor Homo sapiens 144-153 9510155-8 1998 FK506 also reduced CD3/CD28-induced production of IL-3, IL-4, IL-10, TNF-alpha, and IL-6 but augmented that of GM-CSF, IL-5, IFN-gamma, and IL-13. Tacrolimus 0-5 tumor necrosis factor Homo sapiens 69-78 8805102-6 1996 Rapamycin depressed the production of IL-6 and TNF-alpha, and FK506 depressed the production of TNF-alpha. Tacrolimus 62-67 tumor necrosis factor Homo sapiens 96-105 8046352-1 1994 The tumor necrosis factor alpha (TNF-alpha) gene is rapidly transcribed in activated T cells via a calcium-dependent pathway that does not require de novo protein synthesis, but is completely blocked by the immunosuppressive drugs cyclosporin A (CsA) and FK506. Tacrolimus 255-260 tumor necrosis factor Homo sapiens 4-31 8046352-1 1994 The tumor necrosis factor alpha (TNF-alpha) gene is rapidly transcribed in activated T cells via a calcium-dependent pathway that does not require de novo protein synthesis, but is completely blocked by the immunosuppressive drugs cyclosporin A (CsA) and FK506. Tacrolimus 255-260 tumor necrosis factor Homo sapiens 33-42 8046352-3 1994 The ability of analogues of CsA and FK506 to block calcineurin phosphatase activity correlates completely with their ability to inhibit induction of TNF-alpha mRNA, induction of a TNF-alpha promoter reporter plasmid in transiently transfected T cells, and induction of the kappa 3 binding factor in an electrophoretic mobility shift assay. Tacrolimus 36-41 tumor necrosis factor Homo sapiens 149-158 8046352-3 1994 The ability of analogues of CsA and FK506 to block calcineurin phosphatase activity correlates completely with their ability to inhibit induction of TNF-alpha mRNA, induction of a TNF-alpha promoter reporter plasmid in transiently transfected T cells, and induction of the kappa 3 binding factor in an electrophoretic mobility shift assay. Tacrolimus 36-41 tumor necrosis factor Homo sapiens 180-189 8046352-6 1994 Using the panel of CsA and FK506 analogues, we show that calcineurin participates in the induction of TNF-alpha transcription in activated B cells. Tacrolimus 27-32 tumor necrosis factor Homo sapiens 102-111 7518925-2 1994 Antibody directed at surface immunoglobulin (anti-Ig) on B cells has previously been shown to induce a rapid burst of TNF-alpha gene transcription, which can be blocked by the immunosuppressants cyclosporin A (CsA) and FK506. Tacrolimus 219-224 tumor necrosis factor Homo sapiens 118-127 7518925-3 1994 Here, TNF-alpha gene transcription is shown also to be highly and rapidly induced in human B cells after stimulation via the CD40 and interleukin 4 pathways, which similarly is inhibited by CsA and a panel of CsA or FK506 analogues that block calcineurin phosphatase activity. Tacrolimus 216-221 tumor necrosis factor Homo sapiens 6-15 1281550-0 1992 Transcription of the tumor necrosis factor alpha gene is rapidly induced by anti-immunoglobulin and blocked by cyclosporin A and FK506 in human B cells. Tacrolimus 129-134 tumor necrosis factor Homo sapiens 21-48 1281550-5 1992 Moreover, induction of TNF-alpha gene transcription by anti-immunoglobulin was blocked by the immunosuppressants cyclosporin A and FK506. Tacrolimus 131-136 tumor necrosis factor Homo sapiens 23-32 1380951-3 1992 While 1 microgram/ml CSA and 0.1 microgram/ml FK 506 completely suppressed PHA-stimulated accumulation of mRNA for IL2, IL4, IL9, GM-CSF, TNF-alpha and IFN-gamma in PBMC, flu, keto and TGF-beta failed to inhibit any (except TNF-alpha blocked by TGF-beta). Tacrolimus 46-52 tumor necrosis factor Homo sapiens 138-147 1380951-3 1992 While 1 microgram/ml CSA and 0.1 microgram/ml FK 506 completely suppressed PHA-stimulated accumulation of mRNA for IL2, IL4, IL9, GM-CSF, TNF-alpha and IFN-gamma in PBMC, flu, keto and TGF-beta failed to inhibit any (except TNF-alpha blocked by TGF-beta). Tacrolimus 46-52 tumor necrosis factor Homo sapiens 224-233 1371491-5 1992 FK506 or CsA inhibited SEA-induced tumour necrosis factor-alpha (TNF-alpha) production both in monocytes (P less than 0.01) and in lymphocytes (P less than 0.001), at a drug concentration of 1-25 ng/ml for FK506 and 100-500 ng/ml for CsA. Tacrolimus 0-5 tumor necrosis factor Homo sapiens 65-74 1371491-5 1992 FK506 or CsA inhibited SEA-induced tumour necrosis factor-alpha (TNF-alpha) production both in monocytes (P less than 0.01) and in lymphocytes (P less than 0.001), at a drug concentration of 1-25 ng/ml for FK506 and 100-500 ng/ml for CsA. Tacrolimus 206-211 tumor necrosis factor Homo sapiens 65-74 32736525-8 2020 Matrigel tubulation assay were used to investigate the effects of FK506 on TNF-alpha-induced lymphangiogenesis. Tacrolimus 66-71 tumor necrosis factor Homo sapiens 75-84 2472451-1 1989 FK506, a neutral macrolide with immunosuppressive properties, was shown to selectively and rapidly inhibit the accumulation of IL-2 mRNA, as well as the mRNAs of other early (E) phase T cell activation genes such as IL-3, IL-4, GM-CSF, TNF alpha, IFN-gamma, and c-myc in activated human peripheral blood T cells. Tacrolimus 0-5 tumor necrosis factor Homo sapiens 236-245 32180132-7 2020 IFN-gamma potently enhanced TNFA, IL12, HLADRA1 and LRRK2 expression, which was suppressed by FK506, a calcineurin-specific inhibitor, but further enhanced by LRRK2-specific kinase inhibitor (GSK2578215A). Tacrolimus 94-99 tumor necrosis factor Homo sapiens 28-32 32736525-16 2020 Finally, FK506-treated lymphatic endothelial cells show a blunted response to TNF-alpha-mediated lymphangiogenesis. Tacrolimus 9-14 tumor necrosis factor Homo sapiens 78-87 30983820-19 2019 In all, tacrolimus therapy appears to be a viable option for short-term treatment of steroid-refractory acute severe ulcerative colitis besides ciclosporin and anti-tumor necrosis factor alpha treatment. Tacrolimus 8-18 tumor necrosis factor Homo sapiens 165-192 32067305-6 2020 Two patients with severe food allergy responded favorably to conversion from tacrolimus-based immunosuppression to MMF and corticosteroids with reduction in clinical symptoms, total IgE, specific IgE, IL-1ra, IL-4, RANTES, PDGF, MIP-1a, and TNFalpha. Tacrolimus 77-87 tumor necrosis factor Homo sapiens 241-249 31949424-0 2019 Concomitant Treatment with Etanercept and Tacrolimus Synergistically Attenuates Arthritis Progression via Inhibition of Matrix Metalloproteinase-3 Production and Osteoclastogenesis in Human TNF-alpha Transgenic Mice. Tacrolimus 42-52 tumor necrosis factor Homo sapiens 190-199 31087207-0 2019 Axonal Protection by Tacrolimus with Inhibition of NFATc1 in TNF-Induced Optic Nerve Degeneration. Tacrolimus 21-31 tumor necrosis factor Homo sapiens 61-64 31087207-7 2019 A significant increase in TNF protein level was observed in optic nerve 14 days after TNF injection and this increase was prevented by tacrolimus. Tacrolimus 135-145 tumor necrosis factor Homo sapiens 26-29 31087207-7 2019 A significant increase in TNF protein level was observed in optic nerve 14 days after TNF injection and this increase was prevented by tacrolimus. Tacrolimus 135-145 tumor necrosis factor Homo sapiens 86-89 31087207-10 2019 Treatment of tacrolimus significantly ameliorated the TNF-mediated axonal loss. Tacrolimus 13-23 tumor necrosis factor Homo sapiens 54-57 31087207-11 2019 These results suggest that tacrolimus is neuroprotective against axon loss in TNF-induced optic neuropathy and that the effect arises from suppression of the CaN/NFATc1 pathway. Tacrolimus 27-37 tumor necrosis factor Homo sapiens 78-81 32719413-2 2020 The aim of our study was to investigate the short- and long-term efficacy of anti-TNF agents [adalimumab (ADA) and infliximab (IFX)] and TAC in anti-TNF agent- and TAC-naive steroid-refractory UC patients. Tacrolimus 137-140 tumor necrosis factor Homo sapiens 149-152 32719413-2 2020 The aim of our study was to investigate the short- and long-term efficacy of anti-TNF agents [adalimumab (ADA) and infliximab (IFX)] and TAC in anti-TNF agent- and TAC-naive steroid-refractory UC patients. Tacrolimus 164-167 tumor necrosis factor Homo sapiens 82-85 31838663-0 2020 Tacrolimus Inhibits TNF-alpha/IL-17A-Produced pro-Inflammatory Effect on Human Keratinocytes by Regulating IkappaBzeta. Tacrolimus 0-10 tumor necrosis factor Homo sapiens 20-29 31838663-3 2020 This study aimed to investigate the potential regulatory effect of tacrolimus on TNF-alpha/ IL-17A-costimulated human keratinocytes in the mimic psoriatic microenvironment. Tacrolimus 67-77 tumor necrosis factor Homo sapiens 81-90 31838663-8 2020 Tacrolimus significantly inhibited TNF-alpha/IL-17A-induced IL-36gamma, CCL-20, IL-1beta, and S100-A9 expression at gene level and IL-36gamma and CCL-20 expression at protein level. Tacrolimus 0-10 tumor necrosis factor Homo sapiens 35-44 31838663-9 2020 We further discovered TNF-alpha/IL-17A induced significant IkappaBzeta mRNA and protein expression in NHKs, which could be inhibited by tacrolimus. Tacrolimus 136-146 tumor necrosis factor Homo sapiens 22-31 31838663-10 2020 Tacrolimus can inhibit pro-inflammatory synergistic action of TNF-alpha/IL-17A on human keratinocytes by regulating IkappaBzeta expression. Tacrolimus 0-10 tumor necrosis factor Homo sapiens 62-71 30124124-0 2019 Tacrolimus for the treatment of immune-related adverse effects refractory to systemic steroids and anti-tumor necrosis factor alpha therapy. Tacrolimus 0-10 tumor necrosis factor Homo sapiens 104-131 30124124-7 2019 Presented here are three patient cases supporting the use of the calcinuerin inhibitor tacrolimus to treat immune-related adverse effects refractory to corticosteroids and anti-tumor necrosis factor alpha. Tacrolimus 87-97 tumor necrosis factor Homo sapiens 177-204 24707135-4 2014 Active IBD at the time of LT, discontinuation of 5-aminosalicylic acid or azathioprine at the time of LT and use of tacrolimus-based immunosuppression may be associated with an unfavorable outcome of IBD after LT. Anti-tumor necrosis factor alpha (TNFalpha) therapy for refractory IBD may be an effective and safe therapeutic option after LT. Tacrolimus 116-126 tumor necrosis factor Homo sapiens 248-256 29314738-9 2018 CONCLUSION: Adding tacrolimus onto anti-TNF therapy is a promising therapeutic option with sustained benefit for refractory RA patients despite treatment with anti-TNF therapy combined with methotrexate. Tacrolimus 19-29 tumor necrosis factor Homo sapiens 164-167 29520229-0 2018 Tacrolimus Reverses UVB Irradiation-Induced Epidermal Langerhans Cell Reduction by Inhibiting TNF-alpha Secretion in Keratinocytes via Regulation of NF-kappaB/p65. Tacrolimus 0-10 tumor necrosis factor Homo sapiens 94-103 29520229-11 2018 Tacrolimus significantly inhibited UVB irradiation-induced tumor necrosis factor-alpha (TNF-alpha) and nuclear factor kappa B (NF-kappaB)/p65 mRNA and protein expression in HaCaT cells. Tacrolimus 0-10 tumor necrosis factor Homo sapiens 59-86 29520229-11 2018 Tacrolimus significantly inhibited UVB irradiation-induced tumor necrosis factor-alpha (TNF-alpha) and nuclear factor kappa B (NF-kappaB)/p65 mRNA and protein expression in HaCaT cells. Tacrolimus 0-10 tumor necrosis factor Homo sapiens 88-97 29520229-12 2018 Tacrolimus also significantly inhibited high-dose UVB irradiation-induced TNF-alpha expression in cultured tissues. Tacrolimus 0-10 tumor necrosis factor Homo sapiens 74-83 29520229-14 2018 Conclusion: Topical tacrolimus 0.03% could reverse UVB irradiation-induced epidermal LC reduction by inhibiting TNF-alpha secretion in keratinocytes via regulation of NF-kappaB/p65. Tacrolimus 20-30 tumor necrosis factor Homo sapiens 112-121 29527316-2 2018 We aimed to describe the utility of tacrolimus to prevent colectomy during second-line vedolizumab initiation after corticosteroid and anti-TNF treatment failure in paediatric severe colitis. Tacrolimus 36-46 tumor necrosis factor Homo sapiens 140-143 29527316-10 2018 Conclusion: We report real-world data on the outcome of tacrolimus around vedolizumab initiation in paediatric UC or CD after corticosteroid and anti-TNF therapy treatment failure. Tacrolimus 56-66 tumor necrosis factor Homo sapiens 150-153 28060893-8 2017 Molecular features involved in inflammation and immune response contributing to DN progression were significantly downregulated by tacrolimus (e.g. the tumor necrosis factor alpha (TNF), interleukin 4, or interleukin 10). Tacrolimus 131-141 tumor necrosis factor Homo sapiens 152-179 28060893-8 2017 Molecular features involved in inflammation and immune response contributing to DN progression were significantly downregulated by tacrolimus (e.g. the tumor necrosis factor alpha (TNF), interleukin 4, or interleukin 10). Tacrolimus 131-141 tumor necrosis factor Homo sapiens 181-184 28060893-10 2017 CONCLUSION: Patients with DN and elevated TNF levels might benefit from tacrolimus treatment regarding maintaining GFR and reducing inflammation. Tacrolimus 72-82 tumor necrosis factor Homo sapiens 42-45 27181115-2 2017 Tacrolimus (TAC) has proved to show efficacy against inadequate response to tumor necrosis factor alpha inhibitors, yet its add-on effects on TCZ remain unknown. Tacrolimus 0-10 tumor necrosis factor Homo sapiens 76-103 25315214-10 2016 RESULTS: Tacrolimus suppressed the expression of MDC, IP-10, I-309, GRO-alpha, and TNF-alpha in LPS-stimulated THP-1 cells in a dose- and time-dependent manner. Tacrolimus 9-19 tumor necrosis factor Homo sapiens 83-92 25315214-14 2016 CONCLUSION: Tacrolimus suppressed LPS-induced MDC, I-309, IP-10, GRO-alpha, and TNF-alpha expressions in monocytes through the MAPK-ERK pathway; thus, tacrolimus may yield therapeutic efficacy by modulating AD-associated cytokines and chemokines. Tacrolimus 12-22 tumor necrosis factor Homo sapiens 80-89 25315214-14 2016 CONCLUSION: Tacrolimus suppressed LPS-induced MDC, I-309, IP-10, GRO-alpha, and TNF-alpha expressions in monocytes through the MAPK-ERK pathway; thus, tacrolimus may yield therapeutic efficacy by modulating AD-associated cytokines and chemokines. Tacrolimus 151-161 tumor necrosis factor Homo sapiens 80-89 24951257-10 2014 Oral tacrolimus could be used in patients failing anti-TNF therapy. Tacrolimus 5-15 tumor necrosis factor Homo sapiens 55-58 22404745-12 2013 CONCLUSIONS: Topical tacrolimus can be used an effective agent for vitiligo treatment as monotherapy, maybe due to its migration stimulatory action or TNF-alpha inhibitory property, and also as a component in combination therapy with UV treatment, considering the more upregulated MMPs activities are induced and the more effective migrations are feasible by itself than ET-1. Tacrolimus 21-31 tumor necrosis factor Homo sapiens 151-160 25531359-9 2014 In patients not responding to anti-TNF therapy, thalidomide or tacrolimus may be considered. Tacrolimus 63-73 tumor necrosis factor Homo sapiens 35-38 23518805-0 2013 Tacrolimus salvage in anti-tumor necrosis factor antibody treatment-refractory Crohn"s disease. Tacrolimus 0-10 tumor necrosis factor Homo sapiens 27-48 23518805-2 2013 METHODS: We conducted a retrospective study of the use of oral tacrolimus for severe CD refractory to anti-tumor necrosis factor agents. Tacrolimus 63-73 tumor necrosis factor Homo sapiens 107-128 23518805-14 2013 CONCLUSIONS: Oral tacrolimus seems to be safe and effective in some patients with severe CD refractory to anti-tumor necrosis factor therapy, particularly at a mean trough level of 10 to 15 ng/mL. Tacrolimus 18-28 tumor necrosis factor Homo sapiens 111-132 22895606-0 2012 Tacrolimus (FK506) suppresses TNF-alpha-induced CCL2 (MCP-1) and CXCL10 (IP-10) expression via the inhibition of p38 MAP kinase activation in human colonic myofibroblasts. Tacrolimus 0-10 tumor necrosis factor Homo sapiens 30-39 22885734-9 2012 Tumor necrosis factor-alpha as well as IL-1beta induced these chemokines, while tacrolimus inhibited their production and mRNA expression. Tacrolimus 80-90 tumor necrosis factor Homo sapiens 0-27 22895606-0 2012 Tacrolimus (FK506) suppresses TNF-alpha-induced CCL2 (MCP-1) and CXCL10 (IP-10) expression via the inhibition of p38 MAP kinase activation in human colonic myofibroblasts. Tacrolimus 12-17 tumor necrosis factor Homo sapiens 30-39 22132896-13 2012 Finally, inflammatory cytokines, such as tumour necrosis factor (TNF)-alpha and interleukin (IL)-6, showed lower levels in the graft of those animals that had been pretreated with rapamycin or tacrolimus. Tacrolimus 193-203 tumor necrosis factor Homo sapiens 41-75 22895606-5 2012 Tacrolimus (1 microM) suppressed tumor necrosis factor (TNF)-alpha-induced CCL2 and CXCL10 mRNA expression, but did not modulate TNF-alpha-induced interleukin (IL)-6 or CXCL8 mRNA expression. Tacrolimus 0-10 tumor necrosis factor Homo sapiens 33-66 22895606-8 2012 TNF-alpha-induced CCL2 and CXCL10 expression depended on p38 MAP kinase activation, and tacrolimus strongly inhibited the TNF-alpha-induced phosphorylation of p38 MAP kinase. Tacrolimus 88-98 tumor necrosis factor Homo sapiens 122-131 22579702-12 2012 Interestingly, the population of human IL-17(+)IFN-gamma(-) CD4 T cells or IL-17(+)TNF-alpha(+) CD4 T cells were decreased by adding of tacrolimus. Tacrolimus 136-146 tumor necrosis factor Homo sapiens 83-92 22579702-14 2012 Tacrolimus also inhibited expression of IL-17 or TNF-alpha by reducing the proportion of Th17, suggesting that therapeutic effect on Th17-associated disease such as RA, inflammatory bowel disease, multiple sclerosis, psoriasis, or allograft rejection. Tacrolimus 0-10 tumor necrosis factor Homo sapiens 49-58 22576566-3 2012 Recently, new immunomodulators and anti-TNFa agents, such as tacrolimus, infliximab, and adalimumab have been developed and these treatments are available to be treated for patients with refractory UC and CD. Tacrolimus 61-71 tumor necrosis factor Homo sapiens 40-44 21172435-6 2011 However, coincubation of FK506 and SP-A, at concentrations where each component alone did not affect LPS-stimulated macrophage response, significantly inhibited LPS-induced NF-kappaB activation and TNF-alpha secretion. Tacrolimus 25-30 tumor necrosis factor Homo sapiens 198-207 20238216-0 2011 FK506 inhibition of gliostatin/thymidine phosphorylase production induced by tumor necrosis factor-alpha in rheumatoid fibroblast-like synoviocytes. Tacrolimus 0-5 tumor necrosis factor Homo sapiens 77-104 20238216-8 2011 GLS levels in TNF-alpha-stimulated FLSs were reduced by FK506 treatment. Tacrolimus 56-61 tumor necrosis factor Homo sapiens 14-23 21434949-0 2011 Tacrolimus suppresses IL-12/IL23 p40 in Crohn"s disease and heals fistulae refractory to anti-TNF-alpha therapy. Tacrolimus 0-10 tumor necrosis factor Homo sapiens 94-103 19880819-13 2010 Tacrolimus AER was superior to TAC MED at preventing AE IFN-gamma, IL-10, IL-13, monocyte chemoattractant protein-1 chemokine (C-C motif) ligand 5 (RANTES) and TNF-alpha up-regulation. Tacrolimus 0-10 tumor necrosis factor Homo sapiens 160-169 20159692-4 2010 RESULTS: Compared with the control group, high-concentration FK506 (20 ng/ml) significantly inhibited the secretions of IL-2, IL-6, IL-12, IL-17, IFN-gamma, TNF-alpha, GM-CSF and G-CSF. Tacrolimus 61-66 tumor necrosis factor Homo sapiens 157-166 20159692-6 2010 CONCLUSION: FK506 effectively inhibits the secretion of proinflammatory cytokines including IL-6, IFN-gamma and TNF-alpha and also the secretion of IL-2, IL-12, IL-17, GM-CSF and G-CSF. Tacrolimus 12-17 tumor necrosis factor Homo sapiens 112-121 18262659-3 2008 The culture study showed reduced IL-12, IL-17, IFN-gamma, GM-CSF, TNF-alpha and MIP-1beta, and elevated IL-10 in the PBMC from patients who received tacrolimus, which suggests inhibition of T cells and macrophages, and enhancement of type 1 regulatory T cells. Tacrolimus 149-159 tumor necrosis factor Homo sapiens 66-75 18957484-6 2009 RESULTS: Treatment of PBL with leflunomide, cyclosporin A and FK-506 inhibited the IL-15-induced expression of both CD54 and CD69 by PBL, as well as TNF production in co-cultures of activated PBL and THP-1 cells. Tacrolimus 62-68 tumor necrosis factor Homo sapiens 149-152 19153737-0 2009 Adding low dose tacrolimus in rheumatoid arthritis patients with an inadequate response to tumor necrosis factor inhibitor therapies. Tacrolimus 16-26 tumor necrosis factor Homo sapiens 91-112 17880416-3 2007 RESULTS: Upon exposure to ciclosporin A (500 ng/mL) or tacrolimus (25 ng/mL) the number of cytokine expressing T cells was almost completely blocked in neonatal T cells while sirolimus (10 ng/mL) only inhibited intracytoplasmatic tumour necrosis factor alpha (TNF-alpha) expression (mean% positive cells; 4.0 +/- 2.1% vs. 1.09 +/- 0.6%, p = 0.003), but mildly stimulated the intracellular expression of interleukin (IL)-2 (24.4 +/- 6.5% vs. 28.1 +/- 7.1%, p = 0.041). Tacrolimus 55-65 tumor necrosis factor Homo sapiens 260-269 17880416-5 2007 In contrast, the number of cytokine expressing monocytes was not influenced by ciclosporin A and tacrolimus except for a minor decrease of TNF-alpha producing neonatal monocytes after addition of tacrolimus (17.9% vs. 13.9%, p = 0.031). Tacrolimus 196-206 tumor necrosis factor Homo sapiens 139-148 17149058-7 2006 Tacrolimus, cyclosporine, and interferon-alpha-2a should be used generally only if TNF inhibitors have failed as a result of their toxicities. Tacrolimus 0-10 tumor necrosis factor Homo sapiens 83-86 16930148-7 2006 Upon dinucleotide-oligodeoxynucleotide (CpG-ODN) activation, tacrolimus pretreated PDCs showed a significant reduction in the surface expression of co-stimulatory molecules and human leucocyte antigen D-related (HLA-DR) and secreted reduced levels of tumour necrosis factor (TNF)-alpha. Tacrolimus 61-71 tumor necrosis factor Homo sapiens 251-285 17568575-0 2007 Polymorphisms of tumor necrosis factor-alpha, interleukin-10, cytochrome P450 3A5 and ABCB1 in Chinese liver transplant patients treated with immunosuppressant tacrolimus. Tacrolimus 160-170 tumor necrosis factor Homo sapiens 17-44 16181452-5 2005 OBJECTIVES: To explore the effects of FK506 on human KCs in terms of TNF-alpha secretion and to investigate the regulatory pathway involved. Tacrolimus 38-43 tumor necrosis factor Homo sapiens 69-78 16303143-0 2006 Immunosuppressant FK506 inhibits matrix metalloproteinase-9 induction in TNF-alpha-stimulated human hepatic stellate cells. Tacrolimus 18-23 tumor necrosis factor Homo sapiens 73-82 16303143-6 2006 Human HSCs, LI90, were treated with TNF-alpha in the presence of FK506. Tacrolimus 65-70 tumor necrosis factor Homo sapiens 36-45 16303143-10 2006 FK506 suppressed this TNF-alpha-induced NK-kappaB activation, alone with pro-MMP-9 mRNA and protein induction, in HSC. Tacrolimus 0-5 tumor necrosis factor Homo sapiens 22-31 16985094-1 2006 OBJECTIVE: To review the literature on novel immunomodulators such as tumor necrosis factor alpha (TNF-alpha)- and interleukin (IL)-related agents, 6-thioguanine (6-TG), tacrolimus, and leflunomide, and antibiotics such as ornidazole, rifaximin, and ciprofloxacin for the treatment of Crohn"s disease. Tacrolimus 170-180 tumor necrosis factor Homo sapiens 99-108 16181452-11 2005 RESULTS: Our results showed that FK506 dose-dependently downregulated the secretion of TNF-alpha from UVB-irradiated KCs. Tacrolimus 33-38 tumor necrosis factor Homo sapiens 87-96 16181452-15 2005 CONCLUSIONS: Our results indicate that FK506 inhibits TNF-alpha secretion in human KCs via direct regulation of NF-kappaB. Tacrolimus 39-44 tumor necrosis factor Homo sapiens 54-63 15851377-12 2005 NFkappaB activity in TNF-alpha-stimulated synovial cells was suppressed more profoundly by FK506 plus TP (10 ng/ml) than by TP (10 ng/ml) alone. Tacrolimus 91-96 tumor necrosis factor Homo sapiens 21-30 15851377-0 2005 FK506 enhances triptolide-induced down-regulation of cyclooxygenase-2, inducible nitric oxide synthase as well as their products PGE2 and NO in TNF-alpha-stimulated synovial fibroblasts from rheumatoid arthritic patients. Tacrolimus 0-5 tumor necrosis factor Homo sapiens 144-153 15851377-14 2005 CONCLUSION: FK506 enhanced TP-mediated down-regulation of COX-2 and iNOS as well as their products PGE subset2 and NO in human TNF-alpha-stimulated RASF by more profoundly suppressing the activity of NFkappaB. Tacrolimus 12-17 tumor necrosis factor Homo sapiens 127-136 15598440-0 2005 FK506 suppresses E-selectin, ICAM-1 and VCAM-1 expression on vascular endothelial cells by inhibiting tumor necrosis factor alpha secretion from peripheral blood mononuclear cells. Tacrolimus 0-5 tumor necrosis factor Homo sapiens 102-129 15598440-9 2005 These results indicate that FK506 suppresses migration of inflammatory cells through the inhibition of TNFalpha secretion from leukocytes. Tacrolimus 28-33 tumor necrosis factor Homo sapiens 103-111 15377358-9 2004 RESULTS: Our results showed that the release of TGF-beta was upregulated in FK506-treated KCs, particularly in the presence of TNF-alpha, while the expression of iNOS was downregulated. Tacrolimus 76-81 tumor necrosis factor Homo sapiens 127-136 11523700-10 2001 Decreased production of IL-12 and tumor necrosis factor alpha, but not of IL-10, is likely to contribute to the impaired accessory-cell function of tacrolimus- and CsA-treated DCs. Tacrolimus 148-158 tumor necrosis factor Homo sapiens 34-61 15243524-18 2004 Suppression of TNF-alpha after topical tacrolimus application may be associated with repigmentation of vitiligo. Tacrolimus 39-49 tumor necrosis factor Homo sapiens 15-24 12621554-10 2003 NF-kappa B activity in TNF alpha-stimulated synovial cells was suppressed more profoundly by FK506 plus TP (10 microg/L) treatment than those with TP (10 microg/L) alone. Tacrolimus 93-98 tumor necrosis factor Homo sapiens 23-32 11104682-7 2000 Furthermore, mobilization of calcium by A23187 and thapsigargin blocked the TNFalpha-mediated induction of RGS16, which was reversed by EGTA and by the immunosuppressants FK506 and cyclosporin A, suggesting that the calcineurin/NF-AT (nuclear factor of activated T cells) pathway may repress the up-regulation process. Tacrolimus 171-176 tumor necrosis factor Homo sapiens 76-84 11428741-3 2001 OBJECTIVES: We compared the effects of tacrolimus on interleukin (IL)-5 and tumor necrosis factor-alpha (TNF-alpha) production and chemical mediator release from excised human lung tissue with those of steroids. Tacrolimus 39-49 tumor necrosis factor Homo sapiens 76-103 11428741-14 2001 Tacrolimus and dexamethasone significantly inhibited TNF-alpha and IL-5 protein production and mRNA expression. Tacrolimus 0-10 tumor necrosis factor Homo sapiens 53-62 11169223-6 2001 In contrast, cyclosporine A and tacrolimus inhibited the tumour necrosis factor (TNF)-alpha production in response to LPS, but not to PepG and LTA. Tacrolimus 32-42 tumor necrosis factor Homo sapiens 57-91 11121130-0 2000 Suppressive effects of cyclosporin A and FK-506 on superoxide generation in human polymorphonuclear leukocytes primed by tumor necrosis factor alpha. Tacrolimus 41-47 tumor necrosis factor Homo sapiens 121-148